Purpose: Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. It is unclear how frequently this occurs in localized disease and existing detection methods rely on epithelial markers with low specificity and sensitivity. We used multiple methodologies of disseminated tumor cell detection in bone marrow harvested at radical prostatectomy. Materials and Methods: Bone marrow was harvested from 208 clinically localized cases, 16 controls and 5 metastatic cases with peripheral blood obtained from 37 metastatic cases. Samples were evaluated at 4 centers with 4 distinct platforms using antibody enrichment with the AdnaTest (QiagenÒ) or VERSA (versatile exclusion based rare sample analysis), or whole sample interrogation with the RareCyte platform (Seattle, Washington) or HD-SCA (high definition single cell assay) using traditional epithelial markers and prostate specific markers. We investigated the sensitivity and specificity of these markers by evaluating expression levels in control and metastatic cases. Results: EpCAM, NKX3.1 and AR were nonspecifically expressed in controls and in most samples using AdnaTest with no relation to perioperative variables. Only 1 patient with localized disease showed positive results for the prostate specific marker PSA. With the VERSA platform no localized case demonstrated Accepted for publication January 8, 2018. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
disseminated tumor cells. With the RareCyte and HD-SCA platforms only a single patient had 1 disseminated tumor cell. Conclusions: Evaluation across multiple platforms revealed that epithelial markers are nonspecific in bone marrow and, thus, not suitable for disseminated tumor cell detection. Using prostate specific markers disseminated tumor cells were typically not detected in patients with localized prostate cancer.
Key Words: prostatic neoplasms; biomarkers, tumor; neoplastic cells, circulating; bone marrow; neoplasm metastasis DISSEMINATED tumor cells are cancer cells that escape the primary cancer and enter a target organ, representing a first step toward detectable metastasis. 1 A common landing zone for PCa cells is BM. These cells provide an opportunity for the early detection of cancer spread before the development of clinical metastases that are large enough to be captured on conventional imaging. 2 Previously Morgan et al reported that DTCs were present in 72% of men with localized PCa prior to RP. 3 Unexpectedly DTCs were not associated with pathological stage, Gleason grade or PSA. Notably this work relied on epithelial markers to detect cancer cells in BM. There has been recent appreciation of the phenotypic diversity of DTCs and the cellular complexity of BM, which has called into question the reliability of traditional epithelial markers such as CK and EpCAM. The limited sensitivity of epithelial markers was noted recently by McDaniel et al in their study of the detection of CK negative PCa CTCs, which was confirmed by fluorescence in situ hybridization for PTEN and ERG as well as immunofluorescent staining for AR expression. 8 The specificity of epithelial markers is also an issue, given that EpCAM is known to be ubiquitously expressed on normal resident cells of BM, including erythroid progenitor cells and human epidermal Langerhans cells. 4 ,9e11 AR is also not an ideal prostate marker in BM as it facilitates the regulation of hematopoiesis with ubiquitous expression in normal male and female BM. 12 Although NKX3.1 is traditionally considered a prostate specific marker, Uhl en et al found detectable mRNA expression in normal female and male BM tissues. 13 Given the absence of a proven prostate specific marker that is reliable in the BM niche, little is known regarding when or how often PCa cells disseminate to BM as DTCs. Previous studies have demonstrated that 35% of patients with localized PCa who undergo RP will experience biochemical recurrence within 10 years.
14 Thus, it is imperative to investigate DTCs as an early step in the currently incurable process of metastasis since eventually castrate resistance and disease progression will develop in almost all men with metastatic PCa. 15 In the current study we used various immunofluorescence and mRNA expression based rare cell detection platforms to evaluate the presence of DTCs in patients with localized PCa using traditional epithelial and prostate specific markers. Additionally, we investigated the sensitivity and specificity of these markers by evaluating expression levels in controls and metastatic PCa cases.
MATERIALS AND METHODS

Disseminated and Circulating Tumor Cell Detection Assays
Two immunofluorescence based assays were used at 2 separate centers, including the HD-SCA at USC and the AccuCyteÒ at FHCRC (supplementary methods and supplementary Appendix, http://jurology.com/). Additionally, 2 mRNA expression based assays were performed at 2 separate centers, including the AdnaTest (Qiagen) at JHH and the VERSA platform at UW (supplementary methods and supplementary Appendix, http://jurology. com/, and table 1). All methods were verified with spikein controls. Notably the expression patterns of individual cells cannot be queried by mRNA expression applied to a cell population ( fig. 1 ).
Sample Collection and Distribution
All samples were collected consecutively under institutional review board approved protocols with no reported complications. Samples from JHH were distributed to all centers according to preexisting standards for processing time window and shipping (table 1). Patients were tested on a maximum of 2 platforms, given the harvest volume limitation for BM aspiration. RP BM samples were taken using anesthesia prior to incision. Of BM samples 79% were collected from the pubic bone while 21% were collected from the anterior IC. Of the 106 JHH samples 67 (63%) were pubic bone and 39 (37%) were IC. All 43 USC samples (100%) were pubic bone. Of the 18 UW samples 17 (94%) were pubic bone and 1 (6%) was IC. Of the 41 FHCRC samples 37 (90%) were pubic bone and 4 (10%) were IC.
A total of 18 BM samples from clinically localized cases prior to RP were sent to UW for analysis. Of the 41 localized BM samples sent to FHCRC, those of 2 patients (5%) were also evaluated at UW. A total of 43 localized BM samples with 5 matched PB samples were sent to USC for analysis by the HD-SCA assay. The samples of 16 of these patients (37%) were also evaluated at JHH with the AdnaTest.
At JHH BM samples were collected from 106 patients with clinically localized PCa prior to RP and 16 controls specifically defined as individuals without a PCa diagnosis who were female or males who were confirmed not to have prostate cancer. These controls included 1 female with renal cell carcinoma undergoing radical nephrectomy, 1 female with bladder cancer undergoing transurethral bladder tumor resection, 1 male patient undergoing transurethral prostate resection for benign prostatic hyperplasia and 13 males with bladder cancer undergoing radical cystoprostatectomy. In the latter patients the prostate was surgically removed and examined by dedicated urological pathologists who concluded that no prostate adenocarcinoma was present.
A total of 37 PB and 5 BM samples were also collected from metastatic PCa cases. To facilitate the collection of control BM from patients with metastatic PCa, which is a cohort that does not commonly undergo anesthesia, a collaboration was formed with the neurosurgery and orthopedic departments to identify patients requiring urgent stabilization of the spine or weight bearing bones due to PCa bony metastasis to supplement the clinic patients of the medical oncology investigators.
Statistical Analysis
In the JHH localized cohort the associations of preoperative PSA (continuous variable), RP GS (6 vs greater than 6) and pathological stage (pT2 vs greater than pT2) with AR and NXK3.1 expression were evaluated by the Mann-Whitney U test for PSA and the Fisher exact test for GS and stage.
RESULTS
Localized Cohorts
All patients with localized cancer were clinically presumed to have organ confined disease prior to prostatectomy. They had not received any systemic therapy for prostate cancer prior to RP. 
Fred Hutchinson Cancer Research Center Gene Expression Patterns with RareCyte Platform
Two slides from each of the 41 patients with localized PCa were stained and analyzed. Figure 4 , E shows a single DTC identified in BM from 1 patient with pT2N0 disease. DTCs were not detected in the remaining 40 patients. Three clusters of cells with nuclei that were larger than those in the surrounding leukocytes, strong CK, variable EpCAM and no CD45 from the same JHH patient were also detected but they were not classified as DTCs since they lacked AR and 4P staining (supplementary fig.  2 , http://jurology.com/). markers, which are now understood to be nonspecific in BM. 19e22 In the current study we investigated the presence of DTCs across multiple methodologies for rare cell analysis.
With the AdnaTest for mRNA expression EpCAM, NKX3.1 and AR were nonspecifically expressed in control patient BM and in most BM samples with no relation to perioperative variables. Explicitly 125 of all 127 BM samples (98%) contained cells that expressed EpCAM. HOXB13 and PSA were not found in any control sample and yet they were expressed in most samples from patients with metastasis. Only 1 case in the localized PCa cohort was positive for PSA.
Similarly, with the VERSA platform the epithelial markers EpCAM and/or KRT8 were detected in 72% of the patients tested. On each platform NKX3.1 and AR were detected in many samples. On the VERSA platform it was noted that PAP was detected in 89% of patient samples. Importantly PAP and NKX3.1 are generally assumed to be prostate specific markers but these results are consistent with external mRNA expression data showing low expression levels of these 2 genes in normal male and female BM, including 11.1 and 1.3 transcripts per kilobase million for PAP and NKX3.1, respectively. 13 Using VERSA TMPRSS2, PSA and HOXB13 were not detected in any BM derived samples and only 1 case was positive for PSMA. Taken together these results imply that DTCs are a rare event in localized PCa.
The immunofluorescence based platforms offered the ability to evaluate co-localization of markers at the single cell level. The HD-SCA platform detects ARþ/CKþ/CD45e nucleated cells and only 1 localized case was found to have this expression signature. While AR is known to be expressed in normal BM and it was detected in many samples by the VERSA and AdnaTest mRNA based platforms, these results imply that AR is not normally co-localized with the epithelial marker CK in normal tissues. 8 Similarly when using the FHCRC RareCyte platform, prostate DTC was defined using the criteria of 4Pþ/ARþ/CKþ/EpCAMþ/CD45e in only 1 patient. Unfortunately none of these markers is definitively prostate specific in BM since 4P refers to the combination of PSA, which is believed to be prostate specific, and PAP, PSCA and PSMA in 1 immunofluorescence channel.
Given that the VERSA platform revealed PAP expression in most samples, more work is necessary to show that this co-localized expression signature is sufficiently prostate specific. The requirement for AR expression in addition to a prostate cell marker such as PSA provides additional specificity for DTC classification but at the potential cost of sensitivity.
Small case series of 2 to 13 BM samples from patients with PCa were previously studied for epithelial and prostate specific marker expression. 4, 6, 7 One such group used the epithelial marker HEA (human-epithelial antigen) to isolate cells from 11 BM samples, pool them and evaluate individual cells for the expression of NKX3.1, HOXB13 and AR. Only 44 of the total of 85 cells analyzed expressed a prostatic signature. In a larger study of 105 patients with M0 PCa Gu zvi c et al isolated EpCAMþ cells from BM and analyzed the gene expression of 1 prostate specific marker, PSA.
5 They found positive PSA expression in only 1 localized PCa case. Yet given the hypothesis that all EpCAMþ cells represented DTCs, they reasonably only evaluated a small subset of EpCAMþ cells instead of querying the entire cell population. Those investigators were unable to reliably differentiate the gene expression signature of patients with PCa from that of controls.
In contrast to what was previously accepted, the current study suggests that using current detection methods DTCs are uncommon in patients with localized PCa. This could be because DTCs are rare and present at a rate below the limit of detection. Another limitation is that with some methods such as the AdnaTest and the VERSA platform only EpCAMþ cells were captured and evaluated. We now know that epithelial marker negative PCa CTCs have been found in blood and, if this is extrapolated to BM, there may have been EpCAMDTCs that were not identified by our assay. 8 This study was also limited by the small number of control and metastatic BM samples, and the heterogeneity of BM aspirate sites. Future studies will also validate the specificity and sensitivity of PSA and HOXB13 in a larger number of metastatic BM samples, and confirm the nonspecific expression of NKX3.1 and AR in a larger number of control BM samples. It is possible that this study was not powered to detect a significant difference in clinicopathological variables in NKX3.1þ and ARþ cells. However, this analysis is presented to show at least that no difference was detected in the current small cohort. The main evidence for the conclusion that EpCAM, NKX3.1 and AR are unsuitable markers for prostate DTCs is that they were detected in the BM of control patients who were known not to have prostate cancer. 
CONCLUSIONS
Evaluation across multiple platforms revealed that DTCs were rare in localized PCa cases at RP, changing the way that we understand the process of metastasis in prostate cancer. There are potential explanations of these negative results. 1) The step of bone metastasis in which CTCs invade the BM niche as DTCs may have not occurred at the time of prostatectomy in most localized cases, suggesting that the reservoir for recurrent disease is elsewhere. 2) Cells that reside in BM are not detectable by current methodology. 3) DTCs are present in BM at eventual sites of recurrence and not detectable in BM derived from the studied locations. Those rare patients in whom DTCs are detected may be uniquely suited to different treatment than their DTC negative counterparts. As such, we are expanding our cohort of men with high grade cancer to determine whether DTCs are more prevalent in this population. Importantly epithelial markers were found to be nonspecific in BM and, thus, are not suitable for DTC detection.
